The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.24BCNY
635.86M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue (TTM)
269.63MCNY
40.39M · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
-86.01%
vs Biotechnology peers
Updated Oct 24, 2026
Beta
0.4420x
vs all stocks
Updated Oct 24, 2026
52-Week Change
-14.06%
vs all stocks
Updated Oct 24, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
4.24BCNY
635.86M · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
4.35BCNY
652.15M · vs all stocks (USD)
Updated Oct 24, 2026
Forward P/E
-32.90x
vs Biotechnology peers
Updated Oct 24, 2026
Price to Sales (TTM)
14.90x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 15.74×.Updated Oct 24, 2026
Price to Book (MRQ)
2.98x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to Revenue
16.15x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to EBITDA
-35.09x
vs Biotechnology peers
Updated Oct 24, 2026
Gross Margin
3.43%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives -13.17%.Updated Oct 24, 2026
Profit Margin
-86.01%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Margin
-66.23%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Assets (TTM)
-6.69%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Equity (TTM)
-16.29%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
269.63MCNY
40.39M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
0.4280CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
6.30%
vs Biotechnology peers
Updated Oct 24, 2026
Gross Profit (TTM)
-35.51MCNY
-5.32M · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
-124.06MCNY
-18.58M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
-231.91MCNY
-34.74M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
6.33%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
-97.01MCNY
-14.53M · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
-176.36MCNY
-26.42M · vs all stocks (USD)
Updated Oct 24, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Trailing Annual Dividend Rate
0.00CNYUpdated Oct 24, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 24, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 24, 2026
Minority Interest (Equity)
7.68KCNYFY2025 · Dec 31, 2025
Revenue
267.70MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
306.57MCNYFY2025 · Dec 31, 2025
Gross Profit
-38.87MCNYFY2025 · Dec 31, 2025
Operating Income
-206.26MCNY
-30.90M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-233.08MCNYFY2025 · Dec 31, 2025
Income Tax Expense
1.73MCNYFY2025 · Dec 31, 2025
Net Income
-234.81MCNYFY2025 · Dec 31, 2025
EBIT
-224.47MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-100.97MCNYFY2025 · Dec 31, 2025
Research & Development
48.75MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
23.22MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
7.26MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
2.52MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
8.61MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.3700CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.3700CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
635.30MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
635.30MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-234.81MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-252.40KCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-254.51MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-379.43MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
290.55MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-234.81MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
11.36MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-33.99MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
2.94MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-124.92MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-116.92KCNYFY2025 · Dec 31, 2025
Purchase of Investments
-314.00MCNYFY2025 · Dec 31, 2025
Sale of Investments
315.12MCNYFY2025 · Dec 31, 2025
Other Investing Activity
13.38MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-110.53MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
280.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-101.04MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-8.35MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-101.80MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
68.80MCNYFY2025 · Dec 31, 2025
Shares Outstanding
649.04MSharesUpdated Oct 24, 2026
Float Shares
458.15MSharesUpdated Oct 24, 2026
% Held by Insiders
28.21%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
9.60%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
196.38MCNY
29.42M · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
0.3120CNYUpdated Oct 24, 2026
Total Debt (MRQ)
451.35MCNY
67.61M · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
0.3447x
vs Biotechnology peers
Updated Oct 24, 2026
Current Ratio (MRQ)
1.21x
vs Biotechnology peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
2.08CNYUpdated Oct 24, 2026
Total Assets
2.09BCNY
313.35M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
547.16MCNYFY2025 · Dec 31, 2025
Total Liabilities
683.69MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.54BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
239.73MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
443.95MCNYFY2025 · Dec 31, 2025
Cash
286.20MCNYFY2025 · Dec 31, 2025
Cash Equivalents
6.39MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
292.59MCNYFY2025 · Dec 31, 2025
Accounts Receivable
93.59MCNYFY2025 · Dec 31, 2025
Inventory
69.12MCNYFY2025 · Dec 31, 2025
Accounts Payable
95.30MCNYFY2025 · Dec 31, 2025
Short-term Debt
275.02MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
1.96MCNYFY2025 · Dec 31, 2025
Long-term Debt
145.42MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
19.85MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
649.04MCNYFY2025 · Dec 31, 2025
Retained Earnings
-600.35MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.41BCNY
210.93M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
100.00MCNYFY2025 · Dec 31, 2025
52-Week Low
5.01CNYUpdated Oct 24, 2026
52-Week High
9.33CNYUpdated Oct 24, 2026
52-Week Change
-14.06%
vs all stocks
Updated Oct 24, 2026
Beta
0.4420x
vs all stocks
Updated Oct 24, 2026
50-Day MA
7.40CNYUpdated Oct 24, 2026
200-Day MA
6.81CNYUpdated Oct 24, 2026
Avg 10-Day Volume
29.12MSharesUpdated Oct 24, 2026
Avg 30-Day Volume
31.03MSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
-0.3500CNYUpdated Oct 24, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 3.4%, lower than 95% of its Biotechnology peers (median 65.4%)Significant